PRINCIPAL INVESTIGATOR/PROGRAM DIRECTOR: Deisseroth , Albert B. 
GRANTS: 
1991-92 SmithKline Beecham Pharmaceutical, Phase II Study of Topotecan for Patients 
with Advanced Ovarian Cancer, $120,000 
1988-92 CYTOGEN CORPORATION, Phase I/II Trial of Intraperi toneal Monab B72.3-GYK- 
DTPA 90 Y in Patients with Ovarian Carcinoma. $80,000 
1988-89 Bristol Laboratories, Phase II Study of Carboplatin vs VP16 in Ovarian Cancer. 
$72,000 
1988-89 Basic Science Research Grant, Loss of Heterozygosity Studies in Ovarian 
Cancer, M.D. Anderson Cancer Center, Houston, TX. $10,000 
1989 Lilly Research, Phase II Study of LY186641 (Sulfonylurea) In Ovarian Cancer. 
$65,000 
PUBLICATIONS: 
1. Kavanagh JJ, and Claude Nicaise: Carboplatin in refractory epithelial ovarian 
cancer. Sem in Oncol. 16(2) :1, 1989. 
2. Lee JH, Kavanagh JJ, Wharton JT, Wildrick DM, Blick M: Allele Loss at the c-Ha- 
ras l locus in human ovarian cancer. Cancer Res. 49:1220-1222, 1989. 
3. Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer CA, Morris M. Wharton JT: 
Retreatment of patients with recurrent epithelial ovarian cancer with cisplatin- 
based chemotherapy. Obstet Gynecol. 73:798-802, 1989. 
4. Ang P, Kavanagh JJ: Management of recurrent ovarian carcinoma. Am J Clin Oncol 
23(2) : 1295, 1989. 
5. Roberts WS, Kavanagh JJ, Greenberg H, Bryson SCP, LaPolla JP, Townsend PA, Hoffman 
MS, Hewitt S, Cavanagh D: Concomitant radiation therapy and chemotherapy in the 
treatment of advanced squamous carcinoma of the lower female genital tract. Gynecol 
Oncol 34:183-186, 1989. 
6. Baiocchi G, Kavanagh JJ,, and Wharton JT: Endometrioid stromal sarcomas arising 
from ovarian and extraovarian endometriosis: Report of two cases and review of the 
literature. Gynec Oncol, 36(1) : 147-151 , 1990. 
7. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, and Blick M: Frequent Loss of 
Heterozygosity on Chromosomes 6q, 11, and 17 in Human Ovarian Carcinoma. Cancer 
Research 50:2724-2728, 1990. 
8. Hoffman MS, Kavanagh JJ, Roberts WS, LaPolla JP, Fiorica JV, Hewitt S, and Cavanagh 
D. A Phase II evaluation of cisplatin, bleomycin, and mitomycin-C in patients with 
recurrent squamous cell carcinoma of the cervix. Gynec Oncol 40:144-146, 1991. 
9. Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU and Kurzrock R. 
Expression of the macrophage colony-stimulating factor and its receptor in 
gynecologic malignancies. Cancer 67:990-996, 1991. 
10. Rosenblum MG, Kavanach JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva 
EG, Thompson L, Cheung L, Lamki L, Murray JL. - Clinical Pharmacology, Metabolism, 
and Tissue Distribution of 90Y-Labeled Monoclonal Antibody B72.3 After 
Intraperitoneal Administration. J Nat'l. Cancer Inst. 83:1629-1636, 1991. 
^^g9S0i5^t (f Q^4J^arch, Volume 17 PagelQ8* 
1585 ] 
